Navigation Links
Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads


BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ -- Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST. Magnetic cell separation with MACS(R) Technology is the method of choice for the specific isolation of viable cells. A prerequisite for specific cell isolation is the availability of antibodies directed against a specific cell surface antigen. Suitable antibodies against extracellular markers on the astrocyte cell surface were not available until recently, and astrocytes had to be isolated by time-consuming methods, such as generation of astrocyte cultures, which even differ considerably from astrocytes in vivo, or by transgenic approaches.

The new anti-GLAST (ACSA-1) antibody (astrocyte cell surface antigen 1; ACSA-1) recognizes an extracellular epitope of the astrocyte-specific glutamate transporter GLAST (EAAT1), and it shows specific and sensitive labeling of GLAST-positive cells in flow cytometry, immunohistochemistry, and immunocytochemistry.

"The Anti-GLAST (ACSA-1) MicroBead Kit provides the first tool for the straightforward isolation of astrocytes from dissociated brain tissue, and enables the separation of astrocytes based on their expression of GLAST," says Dr. Melanie Jungblut, the responsible R&D Project Manager. "The kit allows for the direct isolation of viable primary astrocytes within one hour, and achieves high purity by minimizing contamination by other cells."

The Anti-GLAST (ACSA-1) MicroBead Kit is exclusively available from Miltenyi Biotec.

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. More than 1,100 employees worldwide develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

Press contact: Prof. Dr. Uwe A. O. Heinlein Corporate Communications, Miltenyi Biotec GmbH Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany Phone: +49-2204-8306-6590 E-mail: .

SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
2. Directors Forum: PEPFAR and the Global AIDS Response
3. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
4. West Pharmaceutical Services, Inc. Appoints New Director
5. Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
10. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... Ltd. (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical ... the simultaneous treatment of various clinical conditions, today announced ... of 3,158,900 American Depository Shares ( ADSs ), each ... to purchase up to 3,158,900 ADSs. The ADSs and ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will be ... Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% ... IguanaMed at a discounted price. , IguanaMed’s mission is to outfit every ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):